Abstract
Type 2 diabetes is increasing in all ancestry groups1. Part of its genetic basis may reside among the rare (minor allele frequency <0.1%) variants that make up the vast majority of human genetic variation2. We analyzed high-coverage (mean depth 38.2x) whole genome sequencing from 9,639 individuals with T2D and 34,994 controls in the NHLBI’s Trans-Omics for Precision Medicine (TOPMed) program2 to show that rare, non-coding variants that are poorly captured by genotyping arrays or imputation panels contribute h2=53% (P=4.2×10−5) to the genetic component of risk in the largest (European) ancestry subset. We coupled sequence variation with islet epigenomic signatures3 to annotate and group rare variants with respect to gene expression4, chromatin state5 and three-dimensional chromatin architecture6, and show that pancreatic islet regulatory elements contribute to T2D genetic risk (h2=8%, P=2.4×10−3). We used islet annotation to create a non-coding framework for rare variant aggregation testing. This approach identified five loci containing rare alleles in islet regulatory elements that suggest novel biological mechanisms readily linked to hypotheses about variant-to-function. Large scale whole genome sequence analysis reveals the substantial contribution of rare, non-coding variation to the genetic architecture of T2D and highlights the value of tissue-specific regulatory annotation for variant-to-function discovery.
Competing Interest Statement
Anubha MahajanAs of January 2020, A.M. is an employee of Genentech, and a holder of Roche stock. Patrick T. EllinorDr. Ellinor is supported by a grant from Bayer AG to the Broad Institute focused on the genetics and therapeutics of cardiovascular disease. Dr. Ellinor has consulted for Bayer AG, Novartis and Quest Diagnostics. Jose FlorezDr. Florez has received a consulting honorarium from Goldfinch Bio. and speaker fees from Novo Nordisk James S. FloydDr. Floyd has consulted for Shionogi Inc Barry I. FreedmanDr. Freedman is a consultant for RenalytixAI and AstraZeneca Pharmaceuticals Steven A. LubitzDr. Lubitz receives sponsored research support from Bristol Myers Squibb / Pfizer, Bayer HealthCare, and Boehringer Ingelheim, and has consulted for Abbott, Quest Diagnostics, Bristol Myers Squibb / Pfizer. Ed SilvermanGrant support from GSK and Bayer Michael H. ChoGrant support from GSK; consulting fees from Genentech Bruce M. PsatyPsaty serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. Stella AslibekyanSA holds equity in 23andMe, Inc. Mark I McCarthyThe views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. M.I.MM.McC. has served on advisory panels for Pfizer, NovoNordisk and Zoe Global, has received honoraria from Merck, Pfizer, Novo Nordisk and Eli Lilly, and research funding from Abbvie, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, NovoNordisk, Pfizer, Roche, Sanofi Aventis, Servier, and Takeda. As of June 2019, M.McC. is an employee of Genentech, and a holder of Roche stock.
Funding Statement
See Supplementary Tables (SUPPL.TABLES.Funding.13NOV2020.xlsx) for funding statements from TOPMed, study, individual and resources.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All study participants provided informed consent, and each study's Institutional Review Board [or ethics review committee] provided approval. Details are provided in provided Supplementary Table (SUPP.TABLE.ParentStudy.Ethics.Statements.xlsx).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be available on the Accelerating Medicines Partnership Type 2 Diabetes Knowledge Portal website.
